ConductScience.org, home

Paper4120640

Inhibition of respiratory virus infection by locally applied interferon.

Merigan TC and 3 others. Lancet, 1973. Cited by 151 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Inhibition of respiratory virus infection by locally applied interferon. Papers, record 4120640. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4120640

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition of respiratory virus infection by locally applied interferon.
PubMed
Journal
Lancet
PubMed
Year
1973
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
151
iCite
Relative citation ratio, by iCite
4.4
iCite
Revised in PubMed
2019-06-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Merigan TCT C
2Reed SES E
3Hall TST S
4Tyrrell DAD A

Source PubMed

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Influenza, HumanMajor topic
InterferonsMajor topic
Respiratory Tract InfectionsMajor topic
RhinovirusMajor topic
Virus DiseasesMajor topic
Administration, Intranasal
Antibodies, Viral
Cells, Cultured
Hemagglutination Inhibition Tests
Humans
Leukocytes
Nasal Mucosa
Neutralization Tests
Organ Culture Techniques
Orthomyxoviridae
Placebos
Trachea

Source PubMed

Cited by75

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.

PMIDTitleJournalYearIn PapersSource
41,515,322Pioneering Role of T.C. Merigan in the Treatment of Various Virus Infections.Molecules2025https://conductscience.org/library/papers/41515322PubMed
36,240,985Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities.Pulm Pharmacol Ther2022https://conductscience.org/library/papers/36240985PubMed
35,618,037Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019.Eur J Pharmacol2022https://conductscience.org/library/papers/35618037PubMed
35,387,044Review: The Nose as a Route for Therapy. Part 2 Immunotherapy.Front Allergy2021https://conductscience.org/library/papers/35387044PubMed
34,101,091Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.J Clin Immunol2021https://conductscience.org/library/papers/34101091PubMed
32,665,127Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?Cytokine Growth Factor Rev2020https://conductscience.org/library/papers/32665127PubMed
32,287,580Chapter 7 Orthomyxovirus infections.Perspect Med Virol1985https://conductscience.org/library/papers/32287580PubMed
32,287,579Chapter 4 Picornavirus infections.Perspect Med Virol1985https://conductscience.org/library/papers/32287579PubMed
32,026,147Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue.World J Pediatr2020https://conductscience.org/library/papers/32026147PubMed
27,713,254Oromucosal Administration of Interferon to Humans.Pharmaceuticals (Basel)2010https://conductscience.org/library/papers/27713254PubMed
27,713,234Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon.Pharmaceuticals (Basel)2009https://conductscience.org/library/papers/27713234PubMed
25,446,140Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.Adv Drug Deliv Rev2015https://conductscience.org/library/papers/25446140PubMed
23,398,960Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.Influenza Other Respir Viruses2013https://conductscience.org/library/papers/23398960PubMed
21,152,181Treatment of hepatitis C infections with interferon: a historical perspective.Hepat Res Treat2010https://conductscience.org/library/papers/21152181PubMed
21,144,866Biodegradable nanogels for oral delivery of interferon for norovirus infection.Antiviral Res2011https://conductscience.org/library/papers/21144866PubMed
21,084,628The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.J Leukoc Biol2011https://conductscience.org/library/papers/21084628PubMed
18,611,565Biological response modifiers and infectious diseases: actual and potential therapeutic agents.Int J Antimicrob Agents1994https://conductscience.org/library/papers/18611565PubMed
18,070,219Clinical uses of interferons.Br J Clin Pharmacol2008https://conductscience.org/library/papers/18070219PubMed
18,049,472Interferons at age 50: past, current and future impact on biomedicine.Nat Rev Drug Discov2007https://conductscience.org/library/papers/18049472PubMed
15,737,415Development of rhinovirus study model using organ culture of turbinate mucosa.J Virol Methods2005https://conductscience.org/library/papers/15737415PubMed

See all 75 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4120640

GET https://conductscience.org/api/papers/v1/4120640/cited_by?page=2